Alliance Pharmaceutical Corp. announces the closing of the acquisition of MDV Technologies Inc.SAN DIEGO--(BUSINESS WIRE)--Nov. 14, 1996--Alliance Pharmaceutical Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ALLP ALLP Aldo Leopold Leadership Program ) Thursday announced that it has completed the acquisition of MDV MDV mucosal disease virus. Technologies Inc. MDV is engaged in the development of a thermo-reversible gel, FloGel, intended for use as an anti-adhesion treatment for persons undergoing abdominal or pelvic surgeries. FloGel is a liquid when cooled and it becomes a gel at body temperature, forming a barrier between tissues. MDV has obtained preliminary human safety data with the product's current formulation, and has performed preclinical studies preclinical studies, n.pl a term used to describe research done before a clinical study. May be laboratory or epidemiologic research. on additional formulations. In addition to the anti-adhesion product, MDV has patents covering the use of the gels for drug delivery and ophthalmic indications. Alliance has been working on the use of perfluorochemical compounds and gels for drug delivery, and the MDV gels should complement the company's efforts. Alliance is a pharmaceutical research and development company with three products currently in clinical studies: Oxygent, an intravascular intravascular /in·tra·vas·cu·lar/ (in?trah-vas´ku-lar) within a vessel. in·tra·vas·cu·lar adj. Within one or more blood vessels. oxygen carrier for use as a temporary ``blood substitute,'' which is being co-developed with affiliates of Johnson & Johnson; LiquiVent, an intrapulmonary ``liquid ventilation'' drug for use in treating patients with acute respiratory failure Respiratory Failure Definition Respiratory failure is nearly any condition that affects breathing function or the lungs themselves and can result in failure of the lungs to function properly. , which is being co-developed with Hoechst Marion Roussel; and Imagent US, an intravenous contrast agent for enhancement of ultrasound images. CONTACT: Alliance Pharmaceutical Corp., San Diego Gwen Rosenberg, 619/558-4300 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion